NBIX Neurocrine Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR पर देखें ↗ बंद अक्ट 2, 2026 10-K/10-Q जुल 31, 2026NBIX स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
NBIX स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
बार ग्रैन्युलैरिटी चयनित अवधि के अनुसार अनुकूलित होती है — बार के लिए ओपन/हाई/लो/क्लोज देखने के लिए चार्ट पर होवर करें।
Neurocrine Biosciences, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
| मेट्रिक | 5Y रुझान | NBIX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| P/E (TTM) | 21.05Y औसत ≈58.9 | ≈58.9 | 19.4 | अति मूल्यांकित | |
| P/S (TTM) | 4.35Y औसत ≈6.5 | ≈6.5 | 7.3 | अल्पमूल्यित | |
| P/B (MRQ) | 3.95Y औसत ≈5.6 | ≈5.6 | 14.5 | अल्पमूल्यित | |
| मूल्य / FCF (TTM) | 16.75Y औसत ≈29.9 | ≈29.9 | · | · | |
| मूल्य / नकदी प्रवाह (TTM) | 16.25Y औसत ≈28.0 | ≈28.0 | 13.6 | अति मूल्यांकित | |
| मूल्य / मूर्त पुस्तक (MRQ) | 9.95Y औसत ≈5.7 | ≈5.7 | · | · | |
| PEG Ratio (PEG अनुपात) | ≈9.0 | · | · | · |
सहकर्मी माध्यिका को प्रति मीट्रिक मानकीकृत आधार पर गणना की जाती है और यह हमेशा इस स्टॉक के लिए दिखाए गए TTM/MRQ आधार से मेल नहीं खा सकती है।
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
| मेट्रिक | 5Y रुझान | NBIX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| परिचालन मार्जिन (TTM) | 23.6%5Y औसत ≈17.0% | ≈17.0% | 15.8% | अनुरूप | |
| EBITDA Margin (EBITDA मार्जिन) | 21.6%5Y औसत ≈17.0% | ≈17.0% | 15.8% | अनुरूप | |
| प्रीटैक्स मार्जिन (TTM) | 27.9%5Y औसत ≈17.2% | ≈17.2% | 16.9% | अनुरूप | |
| शुद्ध लाभ मार्जिन (TTM) | 20.9%5Y औसत ≈12.5% | ≈12.5% | 15.1% | अनुरूप | |
| ROA (TTM) | 15.3%5Y औसत ≈8.4% | ≈8.4% | -0.46% | शीर्ष स्तर | |
| ROE (TTM) | 22.1%5Y औसत ≈11.4% | ≈11.4% | 17.4% | अनुरूप | |
| ROIC | 12.9%5Y औसत ≈10.8% | ≈10.8% | 14.5% | कमजोर |
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
| मेट्रिक | 5Y रुझान | NBIX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| वर्तमान अनुपात (MRQ) | 1.95Y औसत ≈3.2 | ≈3.2 | 3.3 | कम तरलता | |
| Quick Ratio (त्वरित अनुपात) | 1.95Y औसत ≈1.8 | ≈1.8 | 2.5 | कम तरलता |
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
| मेट्रिक | 5Y रुझान | NBIX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Revenue YoY (राजस्व YoY) | 21.4%5Y औसत ≈22.5% | ≈22.5% | · | · | |
| Revenue CAGR 3Y (राजस्व CAGR 3Y) | 24.3%5Y औसत ≈24.6% | ≈24.6% | · | · | |
| Revenue CAGR 5Y (राजस्व CAGR 5Y) | 22.3% | · | · | · | |
| EPS YoY | 41.9%5Y औसत ≈25.0% | ≈25.0% | · | · | |
| Net Income YoY (शुद्ध आय YoY) | 40.2%5Y औसत ≈26.6% | ≈26.6% | · | · | |
| EPS CAGR 3Y | 44.1%5Y औसत ≈27.0% | ≈27.0% | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | |
| Net Income CAGR 3Y (शुद्ध आय CAGR 3Y) | 45.8%5Y औसत ≈29.0% | ≈29.0% | · | · | |
| Net Income CAGR 5Y (शुद्ध आय CAGR 5Y) | 3.3% | · | · | · |
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
| मेट्रिक | 5Y रुझान | NBIX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Asset Turnover (परिसंपत्ति टर्नओवर) | 0.75Y औसत ≈0.7 | ≈0.7 | 0.6 | अनुरूप | |
| Inventory Turnover (इन्वेंटरी टर्नओवर) | 0.85Y औसत ≈0.8 | ≈0.8 | 1.6 | कमजोर | |
| Receivables Turnover (प्राप्य टर्नओवर) | 4.95Y औसत ≈5.4 | ≈5.4 | 7.0 | कमजोर | |
| Revenue / Employee (राजस्व / कर्मचारी (रिपोर्ट की गई हेडकाउंट, यफाइनांस)। व्युत्पन्न — संग्रहीत SEC-XBRL अवधारणा नहीं है।) | ≈$1.1M | · | · | · |
मान · ≈ 5Y औसत · उद्योग माध्य · माध्य के सापेक्ष निर्णय
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | रिपोर्ट | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|---|
| 30 जून 2026 | जुल 28, 2026 | $1.39 | $1.37 | 1.5% |
| 31 मार्च 2026 | $1.91 | $1.20 | 59.5% | |
| 31 दिसमबर 2025 | $1.91 | $1.20 | 59.5% | |
| 30 सितमबर 2025 | $2.04 | $1.62 | 26.1% | |
| 30 जून 2025 | $1.06 | $0.99 | 7.0% | |
| 31 मार्च 2025 | $0.08 | $0.56 | -85.6% |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
बैलेंस शीट
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
नकदी प्रवाह
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
लाभप्रदता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
दक्षता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
प्रति शेयर
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.50 | $26.05 | $22.61 | $17.70 | $14.48 | $12.04 | $6.90 | $5.29 | $4.19 | $3.62 | · | $2.73 | |
| Revenue / Share | $27.91 | $22.71 | $18.68 | $15.05 | $11.58 | $10.69 | $8.23 | $4.73 | $1.83 | $0.17 | · | $0.00 | |
| Cash Flow / Share | $7.64 | $5.74 | $3.86 | $3.43 | $2.62 | $2.34 | $1.59 | $1.06 | $-1.07 | $-1.22 | · | $-0.63 | |
| Cash / Share | $7.12 | $2.34 | $2.54 | $2.72 | $3.59 | $2.00 | $1.22 | $1.56 | $2.87 | $0.96 | · | $0.41 | |
| EPS (TTM) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 |
विकास दरें
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
आय विवरण
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | · | 99,400,000 | 99,000,000 | 99,700,000 | · | 101,100,000 | 100,800,000 | 99,800,000 | · | 97,900,000 | 97,600,000 | 97,100,000 | · | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | · | 102,500,000 | 101,000,000 | 102,500,000 | · | 104,300,000 | 103,900,000 | 103,600,000 | · | 101,100,000 | 100,200,000 | 97,100,000 | · | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
बैलेंस शीट
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
नकदी प्रवाह
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
लाभप्रदता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
दक्षता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
प्रति शेयर
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $36.35 | $33.87 | · | $30.13 | $27.22 | $25.61 | · | $26.87 | $24.87 | $23.72 | · | $20.39 | $18.99 | $17.28 | · | $16.07 | |
| Revenue / Share | $9.20 | $7.88 | · | $7.76 | $6.81 | $5.59 | · | $5.96 | $5.68 | $4.97 | · | $4.93 | $4.52 | $4.33 | · | $3.92 | |
| Cash Flow / Share | · | $1.41 | · | · | · | $0.63 | · | · | · | $1.26 | · | · | · | $-1.29 | · | · | |
| Cash / Share | $3.27 | $2.65 | · | $3.41 | $2.67 | $1.96 | · | $3.45 | $1.38 | $3.94 | · | $2.99 | $1.64 | $1.06 | · | $2.21 | |
| EPS (TTM) | $6.83 | $6.50 | · | $4.18 | $3.38 | $2.95 | · | $3.78 | $3.36 | $3.68 | · | $1.89 | $1.76 | $0.63 | · | $0.58 |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.37B | $3.10B | · | $2.68B | $2.51B | $2.41B | · | $2.24B | $2.12B | $1.98B | · | $1.78B | $1.67B | $1.60B | · | $1.39B | |
| Net Income TTM | $706M | $669M | · | $428M | $348M | $306M | · | $386M | $339M | $370M | · | $191M | $176M | $64M | · | $58M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 24.7 | 20.3 | · | 33.6 | 37.2 | 37.5 | · | 30.5 | 41.0 | 37.5 | · | 59.5 | 53.6 | 160.7 | · | 183.1 | |
| P/S | 5.1 | 4.3 | · | 5.2 | 5.0 | 4.5 | · | 5.2 | 6.6 | 7.0 | · | 6.2 | 5.5 | 6.2 | · | 7.3 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| Earnings Yield | 4.0% | 4.9% | · | 3.0% | 2.7% | 2.7% | · | 3.3% | 2.4% | 2.7% | · | 1.7% | 1.9% | 0.62% | · | 0.55% |
सबसे हाल की अवधि बाईं ओर · शून्य मान इस प्रकार दिखाए गए हैं ·
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| राजस्व | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| परिचालन मार्जिन % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| शुद्ध आय | $479M | $341M | $250M | $154M | $90M |
| तनुकरणित EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| त्वरित अनुपात | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $749M | $557M | $362M | $323M | $233M |
संस्थागत मालिक (13F) 825 फाइलर्स · $18.1B कुल · तिथि अनुसार 30 सितमबर 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 148 (+50 पिछली तिमाही की तुलना में) | 62 (-36 पिछली तिमाही की तुलना में) | 317 (+16 पिछली तिमाही की तुलना में) | 226 (+12 पिछली तिमाही की तुलना में) | +587K |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| BlackRock, Inc. | $2310885707 | 13711607 | 12.75% | शेयर |
| VANGUARD GROUP INC | $1375793692 | 9700301 | 7.59% | शेयर |
| JPMORGAN CHASE & CO | $1088569109 | 6398674 | 6.01% | शेयर |
| Dodge & Cox | $941218594 | 5584707 | 5.19% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838307078 | 4974083 | 4.63% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $766048708 | 4545339 | 4.23% | शेयर |
| STATE STREET CORP | $739126759 | 4385598 | 4.08% | शेयर |
| AQR CAPITAL MANAGEMENT LLC | $643472716 | 3818037 | 3.55% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $393680402 | 2335897 | 2.17% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $359607676 | 2138777 | 1.98% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $349922479 | 2076260 | 1.93% | शेयर |
| Vestal Point Capital, LP | $316845800 | 1880000 | 1.75% | शेयर |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $251858951 | 1494259 | 1.39% | शेयर |
| MORGAN STANLEY | $222231858 | 1318607 | 1.23% | शेयर |
| RTW INVESTMENTS, LP | $213689740 | 1267925 | 1.18% | शेयर |
| NORTHERN TRUST CORP | $212306405 | 1259717 | 1.17% | शेयर |
| Invesco Ltd. | $181565621 | 1077317 | 1.00% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $164200136 | 974279 | 0.91% | शेयर |
| NORGES BANK | $164132866 | 973880 | 0.91% | शेयर |
| FIRST TRUST ADVISORS LP | $155578851 | 923125 | 0.86% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $123525529 | 732877 | 0.68% | शेयर |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122375286 | 726112 | 0.68% | शेयर |
| TWO SIGMA ADVISERS, LP | $119504823 | 842592 | 0.66% | शेयर |
| Bank of New York Mellon Corp | $117826993 | 699125 | 0.65% | शेयर |
| Swedbank AB | $109730107 | 651082 | 0.61% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $109170737 | 647763 | 0.60% | शेयर |
| IEQ CAPITAL, LLC | $107913614 | 640304 | 0.60% | शेयर |
| GOLDMAN SACHS GROUP INC | $106495877 | 631892 | 0.59% | शेयर |
| BANK OF AMERICA CORP /DE/ | $104382489 | 619352 | 0.58% | शेयर |
| VICTORY CAPITAL MANAGEMENT INC | $104238729 | 618499 | 0.58% | शेयर |
| Man Group plc | $101292738 | 601019 | 0.56% | शेयर |
| ROYAL BANK OF CANADA | $98337000 | 583476 | 0.54% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $97778953 | 580170 | 0.54% | शेयर |
| FRANKLIN RESOURCES INC | $93211316 | 553068 | 0.51% | शेयर |
| UBS Group AG | $92009492 | 545937 | 0.51% | शेयर |
| Caisse de depot et placement du Quebec | $91002327 | 539961 | 0.50% | शेयर |
| ARMISTICE CAPITAL, LLC | $90307457 | 535838 | 0.50% | शेयर |
| AMERIPRISE FINANCIAL INC | $84660571 | 502267 | 0.47% | शेयर |
| PRIMECAP MANAGEMENT CO/CA/ | $82807988 | 491340 | 0.46% | शेयर |
| Hood River Capital Management LLC | $79082184 | 469233 | 0.44% | शेयर |
| Nuveen, LLC | $77408341 | 459301 | 0.43% | शेयर |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $75318261 | 571719 | 0.42% | शेयर |
| Pictet Asset Management Holding SA | $72751030 | 430635 | 0.40% | शेयर |
| Rockefeller Capital Management L.P. | $62955982 | 373548 | 0.35% | शेयर |
| Fiera Capital Corp | $62895914 | 373192 | 0.35% | शेयर |
| Gotham Asset Management, LLC | $62622213 | 371568 | 0.35% | शेयर |
| JANUS HENDERSON GROUP PLC | $61515240 | 466977 | 0.34% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $60767710 | 461270 | 0.34% | शेयर |
| Vinva Investment Management Ltd | $58838530 | 346109 | 0.32% | शेयर |
| AustralianSuper Pty Ltd | $58817535 | 348993 | 0.32% | शेयर |
कार्यकर्ता और 5%+ मालिक 1 होल्डिंग
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 फाइलिंग | 24 फ़रवरी 2023 | · | प्रारंभिक फाइलिंग | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
कंपनी के अंदरूनी सूत्र 41 इनसाइडर्स · 22 अधिकारी · 15 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | 11 सितमबर 2026 F | 154728 | 0 | 3 | $-4872890 |
| Matt Abernethy | Chief Financial Officer | 14 सितमबर 2026 S | 42808 | 0 | 1 | $-363289 |
| Timothy Coughlin | Chief Financial Officer | 6 फ़रवरी 2017 S | 137961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | 6 फ़रवरी 2017 A | · | 0 | 0 | $0 |
| David W. Boyer | Chief Corp. Affairs Officer | 14 सितमबर 2026 S | 8722 | 0 | 2 | $-739070 |
| Ingrid Delaet | Chief Regulatory Officer | 11 सितमबर 2026 F | 18289 | 0 | 5 | $-3747962 |
| Jude Onyia | Chief Scientific Officer | 11 सितमबर 2026 F | 22647 | 0 | 2 | $-3473580 |
| Sanjay Chandru Keswani | Chief Medical Officer | 11 सितमबर 2026 F | 3281 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | 11 सितमबर 2026 F | 24025 | 0 | 5 | $-5770377 |
| Eric Benevich | Chief Commercial Officer | 11 सितमबर 2026 F | 67297 | 0 | 2 | $-1238918 |
| Darin Lippoldt | Chief Legal Officer | 11 सितमबर 2026 F | 56793 | 0 | 5 | $-4196071 |
| Eiry Roberts | Chief Medical Officer | 13 फ़रवरी 2025 M | 35640 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 8 फ़रवरी 2023 S | 42337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | 31 जनवरी 2022 A | 82273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | 8 फ़रवरी 2021 A | 157651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | 5 फ़रवरी 2018 A | 55946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 31 अगस्त 2011 A | 118256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | 27 फ़रवरी 2008 A | 9667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | 19 जनवरी 2006 A | 5023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | 3 जून 2005 A | 11216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | 18 फ़रवरी 2005 A | · | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | 18 दिसमबर 2003 S | 7966 | 0 | 0 | $0 |
| Kevin Charles Gorman | निदेशक | 11 सितमबर 2026 F | 517797 | 0 | 1 | $-37824431 |
| SHERWIN STEPHEN A | निदेशक | 2 सितमबर 2026 G | 14860 | 0 | 5 | $-4132990 |
| Leslie V Norwalk | निदेशक | 29 जुलाई 2026 M | 2430 | 0 | 5 | $-1973882 |
| Johanna Mercier | निदेशक | 27 मई 2026 A | 6853 | 0 | 0 | $0 |
| William H Rastetter | निदेशक | 27 मई 2026 A | 43678 | 0 | 1 | $-2732760 |
| Christine A Poon | निदेशक | 27 मई 2026 A | 4753 | 0 | 0 | $0 |
| POPS RICHARD F | निदेशक | 27 मई 2026 A | 37798 | 0 | 1 | $-2364750 |
| LYONS GARY A | निदेशक | 27 मई 2026 A | 122141 | 0 | 1 | $-2289150 |
| MORROW GEORGE J | निदेशक | 27 मई 2026 A | 10386 | 0 | 1 | $-2150550 |
| Alfred Sandrock | निदेशक | 22 मई 2019 A | · | 0 | 0 | $0 |
| Corinne H Nevinny | निदेशक | 24 मई 2018 A | 43283 | 0 | 0 | $0 |
| Thomas W Mitchell | निदेशक | 28 मई 2015 A | 1000 | 0 | 0 | $0 |
| VALE WYLIE W | निदेशक | 25 मई 2011 A | 231372 | 0 | 0 | $0 |
| Adrian Adams | निदेशक | 30 जून 2006 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | 27 मई 2026 A | 4088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | · | 22 मई 2017 A | 56042 | 0 | 0 | $0 |
| HAWRAN PAUL W | · | 18 सितमबर 2006 J | 132000 | 0 | 0 | $0 |
| Lawrence Steinman | · | 2 मार्च 2005 S | 15500 | 0 | 0 | $0 |
| CONLON PAUL J | · | 16 दिसमबर 2003 S | 57335 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
ईटीएफ स्वामित्व 104 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| IBRN · iShares Trust | 3.75% | 1793 SH | 11 सितमबर 2026 | दैनिक |
| MCOW · Pacer Funds Trust | 2.57% | 164 NS | 31 जुलाई 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2.56% | 76511 SH | 1 अक्टूबर 2026 | दैनिक |
| BUL · Pacer Funds Trust | 2.15% | 16896 NS | 31 जुलाई 2026 | N-PORT |
| CVSM · Elevation Series Trust | 2.04% | 11525 NS | 31 जुलाई 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1.96% | 22570 SH | 1 अक्टूबर 2026 | दैनिक |
| JMID · Janus Detroit Street Trust | 1.93% | 2742 NS | 31 जुलाई 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 1.90% | 236 NS | 31 जुलाई 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1.90% | 460 NS | 31 जुलाई 2026 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1.77% | 667778 SH | 1 अक्टूबर 2026 | दैनिक |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.67% | 105135 NS | 31 जुलाई 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1.64% | 56706 SH | 1 अक्टूबर 2026 | दैनिक |
| BBP · ETFis Series Trust I | 1.44% | 8494 NS | 31 जुलाई 2026 | N-PORT |
| CSMD · Professionally Managed Portfolios | 1.18% | 32094 NS | 31 जुलाई 2026 | N-PORT |
| IBB · iShares Trust | 1.14% | 755021 SH | 11 सितमबर 2026 | दैनिक |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 1.11% | 7516 NS | 31 जुलाई 2026 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1.06% | 24859 SH | 1 अक्टूबर 2026 | दैनिक |
| JSMD · Janus Detroit Street Trust | 1.05% | 66455 NS | 31 जुलाई 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.94% | 7190 SH | 1 अक्टूबर 2026 | दैनिक |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.89% | 99214 SH | 19 अगस्त 2026 | दैनिक |
| COWG · Pacer Funds Trust | 0.78% | 103520 NS | 31 जुलाई 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.73% | 399 NS | 31 जुलाई 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0.73% | 59895 SH | 1 अक्टूबर 2026 | दैनिक |
| LSEQ · Harbor ETF Trust | 0.72% | 661 NS | 31 जुलाई 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.71% | 20978 NS | 31 जुलाई 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.63% | 12528 NS | 31 जुलाई 2026 | N-PORT |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.63% | 21784 NS | 31 जुलाई 2026 | N-PORT |
| QLV · FlexShares Trust | 0.56% | 5460 NS | 31 जुलाई 2026 | N-PORT |
| ISCG · iShares Trust | 0.52% | 31868 SH | 11 सितमबर 2026 | दैनिक |
| PTMC · Pacer Funds Trust | 0.47% | 11072 NS | 31 जुलाई 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0.46% | 13252 SH | 1 अक्टूबर 2026 | दैनिक |
| USMV · iShares Trust | 0.46% | 697795 SH | 11 सितमबर 2026 | दैनिक |
| VBK · VANGUARD INDEX FUNDS | 0.46% | 1331820 SH | 19 अगस्त 2026 | दैनिक |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.46% | 162408 SH | 19 अगस्त 2026 | दैनिक |
| SMDX · Tidal Trust III | 0.43% | 3374 NS | 31 जुलाई 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.42% | 16429 NS | 31 जुलाई 2026 | N-PORT |
| IWP · iShares Trust | 0.39% | 480949 SH | 11 सितमबर 2026 | दैनिक |
| SDG · iShares Trust | 0.38% | 4071 SH | 11 सितमबर 2026 | दैनिक |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.36% | 44021 NS | 31 जुलाई 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.36% | 1476 NS | 31 जुलाई 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.31% | 46187 NS | 31 जुलाई 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.30% | 24447 NS | 31 जुलाई 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.29% | 8053 NS | 31 जुलाई 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0.25% | 283150 NS | 31 जुलाई 2026 | N-PORT |
| IYH · iShares Trust | 0.25% | 57843 SH | 11 सितमबर 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | 0.24% | 286599 SH | 19 अगस्त 2026 | दैनिक |
| FHLC · FIDELITY COVINGTON TRUST | 0.23% | 45259 NS | 31 जुलाई 2026 | N-PORT |
| SMMD · iShares Trust | 0.21% | 52744 SH | 11 सितमबर 2026 | दैनिक |
| EUSA · iShares, Inc. | 0.20% | 25089 SH | 11 सितमबर 2026 | दैनिक |
| VB · VANGUARD INDEX FUNDS | 0.20% | 2306077 SH | 19 अगस्त 2026 | दैनिक |
| PWS · Pacer Funds Trust | 0.20% | 287 NS | 31 जुलाई 2026 | N-PORT |
| SIZE · iShares Trust | 0.20% | 5417 SH | 11 सितमबर 2026 | दैनिक |
| VXF · VANGUARD INDEX FUNDS | 0.19% | 1153763 SH | 19 अगस्त 2026 | दैनिक |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.19% | 6541 NS | 31 जुलाई 2026 | N-PORT |
| ACWV · iShares, Inc. | 0.18% | 37854 SH | 11 सितमबर 2026 | दैनिक |
| RWK · Invesco Exchange-Traded Fund Trust … | 0.13% | 11381 SH | 1 अक्टूबर 2026 | दैनिक |
| IWR · iShares Trust | 0.11% | 405396 SH | 11 सितमबर 2026 | दैनिक |
| FHEQ · Fidelity Greenwood Street Trust | 0.11% | 6157 NS | 31 जुलाई 2026 | N-PORT |
| ESUM · Strategy Shares | 0.10% | 1133 NS | 31 जुलाई 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.10% | 177 NS | 31 जुलाई 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0.10% | 2270 NS | 31 जुलाई 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 4819 SH | 1 अक्टूबर 2026 | दैनिक |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0.09% | 23838 NS | 31 जुलाई 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.08% | 70759 NS | 31 जुलाई 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.07% | 23694 SH | 1 अक्टूबर 2026 | दैनिक |
| DYNF · BlackRock ETF Trust | 0.07% | 177312 SH | 11 सितमबर 2026 | दैनिक |
| USXF · iShares Trust | 0.06% | 5665 SH | 11 सितमबर 2026 | दैनिक |
| ESMV · iShares Trust | 0.05% | 26 SH | 11 सितमबर 2026 | दैनिक |
| GARP · iShares Trust | 0.05% | 9869 SH | 11 सितमबर 2026 | दैनिक |
| DFAC · Dimensional ETF Trust | 0.05% | 141631 NS | 31 जुलाई 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.05% | 1484 NS | 31 जुलाई 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.04% | 8569 NS | 31 जुलाई 2026 | N-PORT |
| IUSG · iShares Trust | 0.04% | 89338 SH | 11 सितमबर 2026 | दैनिक |
| IWF · iShares Trust | 0.04% | 320069 SH | 11 सितमबर 2026 | दैनिक |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 134662 SH | 19 अगस्त 2026 | दैनिक |
| ESGV · VANGUARD WORLD FUND | 0.03% | 22375 SH | 19 अगस्त 2026 | दैनिक |
| TILT · FlexShares Trust | 0.03% | 3888 NS | 31 जुलाई 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.03% | 20775 NS | 31 जुलाई 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0.02% | 8549 NS | 31 जुलाई 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.02% | 28885 NS | 31 जुलाई 2026 | N-PORT |
| IYY · iShares Trust | 0.02% | 4355 SH | 11 सितमबर 2026 | दैनिक |
| IWB · iShares Trust | 0.02% | 68459 SH | 11 सितमबर 2026 | दैनिक |
| ITOT · iShares Trust | 0.02% | 131068 SH | 11 सितमबर 2026 | दैनिक |
| IWS · iShares Trust | 0.02% | 20508 SH | 11 सितमबर 2026 | दैनिक |
| IWV · iShares Trust | 0.02% | 27012 SH | 11 सितमबर 2026 | दैनिक |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.02% | 16474 SH | 1 अक्टूबर 2026 | दैनिक |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 3193839 SH | 19 अगस्त 2026 | दैनिक |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 16227 SH | 19 अगस्त 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 8342 SH | 19 अगस्त 2026 | दैनिक |
| PRF · Invesco Exchange-Traded Fund Trust | 0.02% | 11591 SH | 1 अक्टूबर 2026 | दैनिक |
| TOK · iShares Trust | 0.02% | 249 SH | 11 सितमबर 2026 | दैनिक |
| URTH · iShares, Inc. | 0.02% | 8440 SH | 11 सितमबर 2026 | दैनिक |
| ACWI · iShares Trust | 0.01% | 30548 SH | 11 सितमबर 2026 | दैनिक |
| DFLV · Dimensional ETF Trust | 0.01% | 4926 NS | 31 जुलाई 2026 | N-PORT |
| DFVX · Dimensional ETF Trust | 0.01% | 323 NS | 31 जुलाई 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 85082 SH | 19 अगस्त 2026 | दैनिक |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 8319 SH | 19 अगस्त 2026 | दैनिक |
| FYEE · Fidelity Greenwood Street Trust | 0.01% | 110 NS | 31 जुलाई 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0.01% | 124 NS | 31 जुलाई 2026 | N-PORT |
| IWD · iShares Trust | 0.01% | 30627 SH | 11 सितमबर 2026 | दैनिक |
| IJH · iShares Trust | · | 3528125 SH | 11 सितमबर 2026 | दैनिक |
| IJK · iShares Trust | · | 582451 SH | 11 सितमबर 2026 | दैनिक |
| XJH · iShares Trust | · | 13736 SH | 8 सितमबर 2026 | दैनिक |
| ISCB · iShares Trust | · | 4526 SH | 11 सितमबर 2026 | दैनिक |
NBIX विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
12-महीने का मूल्य लक्ष्य
29 विश्लेषक · 2026-10-03माध्य लक्ष्य $207.81 +45.1%
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
वित्तीय वर्ष के आधार पर, प्रत्येक कंपनी के पिछले वित्तीय वर्ष के अंत के बंद भाव के अनुसार कीमतें।
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | · |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | · |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | · |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
ट्रेडिंग सिग्नल प्रवेश मूल्य और जोखिम/इनाम अनुपात के साथ हालिया खरीद/बिक्री संकेत
अभी कोई खुला सिग्नल नहीं — कोई कार्ड भरा नहीं है, और यह ईमानदार है।
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर फुल फंडामेंटल्स में किसी भी पंक्ति के बगल में + पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।